Tigecycline is the first agent in the new class of glycylcycline antibiotics. It's expanded broad spectrum of activity, with demonstrated efficacy as monotherapy against clinically important Gram-positive and Gram-negative pathogens include also anerobes and antibiotic-resistant isolates. It is presented the case of a 54 years old man, recently diagnosed with HIV infection, that had high fever and skin abscesses. The laboratory investigations showed a Systemic Inflammatory Response Syndrome. After 10 days of treatment with Tygacil, 100 mg at first, then 50 mg/12 hours, surgical incision and drainage, antiinflammatory and symptomatic treatment, the patient's symptoms disappeared and we started also the antiretroviral therapy.
Tigecycline For Skin Infection With SIRS In Immunocompromised Host Introduction
Tigecycline, the first agent in the new class of glycylcycline antibiotics, has an expanded broad spectrum of activity, with demonstrated efficacy as monotherapy against clinically important Grampositive and Gram-negative pathogens and anerobes, including antibiotic-resistant isolates [1, 2, 3, 4] .
The drug is efficacious in patients with secondary peritonitis, abcesses, complicated skin and soft tissue infection and is well tolerated without any adverse events [5] .
It is presented the case of a patient, recently diagnosed with HIV infection, that had high fever and skin abscesses, treated with Tigecycline.
Materials and methods
A 54-years old, male patient, recently diagnosed with AIDS, was admitted in our clinic because of fever during the last 10 days.
On clinical examination we found two old abscesses, one in perianal region, and the other on the anterior half part of the left calf (Figure 1 ) 
Results
After 10 days of treatment that consisted of: Tygacil, 100 mg at first, then 50 mg/12 hours, surgical incision and drainage, antiinflammatory and symptomatic treatment, the patient's symptoms disappeared and we started also the antiretroviral therapy.
Conclusions
The evolution of this case and the conclusions of many clinical trials and studies shows us that Tygecycline demonstrated efficacy as monotherapy against severe infections, even in immunocompromised patients and antibioticresistant strains.
